vcvibes

Atlas Venture Life Science Advisors, LLC

SEC exempt reporting adviser (venture capital exemption).

Website
HTTP://WWW.ATLASVENTURE.COM
HQ
MA
Visit their website

Atlas Venture Life Science Advisors, LLC says it builds breakthrough biotechnology companies in life sciences. Its listed portfolio includes Kymera Therapeutics, which develops small molecule protein degrader medicines, Intellia Therapeutics, which works on gene editing therapies, and Dyne Therapeutics, which focuses on targeted therapies for serious muscle diseases. The firm also lists a team of partners, principals, and senior associates.

01 · Says / Does

TagSaysDoesHistorically (to 2020)
StagesNot statedNot enough dated dealsSeries A, Series B, Growth, Seed
SectorsBiotechNot enough dated dealsBiotech, Healthtech, Media, Enterprise SaaS, Hardware, Data analytics
RegionsNot statedNot enough dated dealsMA, CA

Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.

Historical focus (through 2020), derived from historical deal data.

YearDealsTop sectors
19983Biotech, Healthtech, Hardware
19998Logistics, Media, Data analytics
200033Hardware, Media, Enterprise SaaS
200117Media, Ecommerce, Hardware
200216Biotech, Healthtech, Media
200324Healthtech, Biotech, Hardware
200421Hardware, Biotech, Healthtech
200527Hardware, Biotech, Enterprise SaaS
200631Media, Biotech, Hardware
200737Biotech, Hardware, Healthtech
200818Biotech, Healthtech, Media
200920Biotech, Hardware, Data analytics
201019Biotech, Data analytics, Healthtech
201123Data analytics, Biotech, Consumer
201243Data analytics, Media, Biotech
201349Enterprise SaaS, Data analytics, Media
201457Biotech, Enterprise SaaS, Healthtech
201514Biotech, Healthtech, Medical devices
20168Biotech, Healthtech, Medical devices
201714Biotech, Healthtech, Medical devices
201813Biotech, Healthtech, Life sciences and research tools
20194Biotech, Healthtech
20209Biotech, Healthtech, Life sciences and research tools

Stage mix over time

2010 Seed: 32010 Series A: 12010 Series B: 62010 Growth: 6102011 Seed: 82011 Series A: 52011 Growth: 4112012 Seed: 92012 Series A: 132012 Series B: 62012 Growth: 5122013 Seed: 222013 Series A: 162013 Series B: 52013 Growth: 3132014 Seed: 172014 Series A: 212014 Series B: 62014 Growth: 9142015 Series A: 52015 Series B: 72015 Growth: 2152016 Seed: 22016 Series A: 42016 Series B: 2162017 Series A: 52017 Series B: 32017 Growth: 5172018 Series A: 72018 Series B: 52018 Growth: 1182019 Series A: 3192020 Series A: 42020 Series B: 42020 Growth: 120212223242526
  • Pre-seed
  • Seed
  • Series A
  • Series B
  • Growth
Share of rounds by stage, per year. Striped years have fewer than 3 rounds.Historical focus (through 2020), derived from historical deal data.
Rounds by stage and year
YearPre-seedSeedSeries ASeries BGrowth
201003166
201108504
2012091365
20130221653
20140172169
201500572
201602420
201700535
201800751
201900300
202000441
202100000
202200000
202300000
202400000
202500000
202600000

02 · Fund history

FundYearSizeStatus
Atlas Venture Fund XIV, L.P.

Atlas Venture creates and builds breakthrough biotechnology companies in life sciences, partnering with life science entrepreneurs and launching startups from its incubator to translate groundbreaking science into new medicines. Inferred from the firm's website

2024$450M (Form D)Open, writing first checks
Atlas Venture Fund XIII, L.P.

Atlas Venture creates and builds breakthrough biotechnology companies in life sciences, partnering with life science entrepreneurs and launching startups from its incubator to translate groundbreaking science into new medicines. Inferred from the firm's website

2022$450M to $535.4M (Form D and SEC adviser filing)Late investment period

03 · People across funds

04 · Recent deals

No dated deals found yet.

05 · Latest from the firm

No news from the firm's website yet.

06 · Sources

  1. HTTP://WWW.ATLASVENTURE.COM
  2. https://atlasventure.com/portfolio/
  3. https://atlasventure.com/team?_sft_team_category=investment-team
  4. https://atlasventure.com/

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026